This Article Full Text Full Text (PDF) All Versions of this Article: 39/7/2177    most recent STROKEAHA.107.496646v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by McCormick, M. T. Articles by Walters, M. R. Search for Related Content PubMed PubMed Citation Articles by McCormick, M. T. Articles by Walters, M. R. Related Collections Other Stroke Treatment - Medical

(Stroke. 2008;39:2177.)
© 2008 American Heart Association, Inc.

Emerging Therapies

Management of Hyperglycemia in Acute Stroke

How, When, and for Whom?

Michael T. McCormick, MRCP; Keith W. Muir, MD, FRCP; Christopher S. Gray, MD, FRCP Matthew R. Walters, MD, FRCP

From the Divisions of Clinical Neurosciences (M.T.M., K.W.M.) and Cardiovascular and Medical Sciences (M.R.W.), University of Glasgow; and the School of Clinical Medical Sciences (C.S.G.), Newcastle University, UK.

Correspondence to Matthew R. Walters, University of Glasgow, Division of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK. E-mail m.walters@clinmed.gla.ac.uk

Marc Fisher MD Kennedy Lees MD Section Editors:

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Current acute therapies for ischemic stroke are limited. Only a small proportion of stroke patients are eligible to receive fibrinolytic therapy; clinical trials of neuroprotectant drugs have yielded disappointing results, and other potential interventions are at very early stages of development.

Against this background, coordinated stroke unit care is, however, of proven benefit; reduced mortality, institutionalization and dependency. Clinical trials demonstrating the benefit of stroke unit care have recognized the potential but unproven benefits that may be realized through rigorous physiological monitoring and intervention to correct derangements in the acute phase.

This review will discuss the complex relationship between hyperglycemia and stroke, with particular emphasis on the role of glycemic control in the acute stroke patient.

Whether acute hyperglycemia is a cause of neurological deterioration or an epiphenomenon, is a distinction pivotal in management of the stroke patient with hyperglycemia. Poststroke hyperglycemia is common and, at least in nondiabetic individuals, is associated with a poorer stroke outcome when compared to normoglycemia.^1,2 In a systematic review of observational studies examining the prognostic significance of hyperglycemia in acute stroke, the unadjusted relative risk of in-hospital or 30-day mortality was 3.07 (95% CI, 2.50 to 3.79) in nondiabetic patients and 1.30 (95% CI, 0.49 to 3.43) in those with diabetes.³ The relative risk of poor functional outcome in hyperglycemic nondiabetic patients was 1.41 (95% CI 1.16 to 1.73). Using MRI it has been demonstrated that in patients with acute perfusion diffusion mismatch within 24 hours of stroke onset, acute hyperglycemia correlates with reduced . . . [Full Text of this Article]